You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Chartwell Rx Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHARTWELL RX, and what generic and branded alternatives to CHARTWELL RX drugs are available?

CHARTWELL RX has four hundred and twenty-two approved drugs.

There is one tentative approval on CHARTWELL RX drugs.

Summary for Chartwell Rx

US Patents:	0
Tradenames:	299
Ingredients:	284
NDAs:	422

Drugs and US Patents for Chartwell Rx

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CAPTOPRIL	captopril	TABLET;ORAL	074519-002	Feb 13, 1996		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	CEFIXIME	cefixime	FOR SUSPENSION;ORAL	206144-001	Nov 17, 2017		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	ACYCLOVIR	acyclovir	OINTMENT;TOPICAL	212495-001	Apr 7, 2020	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	PROPRANOLOL HYDROCHLORIDE	propranolol hydrochloride	TABLET;ORAL	070663-001	Jun 13, 1986		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET, EXTENDED RELEASE;ORAL	091395-004	Aug 27, 2012	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	AMLODIPINE BESYLATE	amlodipine besylate	TABLET;ORAL	076692-003	Jul 20, 2007	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	LACTULOSE	lactulose	SOLUTION;ORAL	209517-001	Nov 23, 2018	AA	RX	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell Rx

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Rx	LIMBITROL	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-001	Approved Prior to Jan 1, 1982	4,316,897	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-005	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-006	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-008	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-007	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-004	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	LIMBITROL DS	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-002	Approved Prior to Jan 1, 1982	4,316,897	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.